Syndax Pharmaceuticals, Inc. Interest Expense
Syndax Pharmaceuticals, Inc. (SNDX) reported Interest Expense of $45.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-01.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-08-01
- Syndax Pharmaceuticals, Inc. interest expense for the quarter ending 2024-06-30 was $45.00K, a 28.57% increase year-over-year.
- Syndax Pharmaceuticals, Inc. interest expense for the quarter ending 2024-03-31 was $55.00K, a 37.50% increase year-over-year.
- Syndax Pharmaceuticals, Inc. interest expense for the quarter ending 2023-12-31 was $63.00K, a 46.51% increase year-over-year.
- Syndax Pharmaceuticals, Inc. interest expense for the quarter ending 2023-09-30 was $70.00K, a 96.00% decline year-over-year.
- Syndax Pharmaceuticals, Inc. interest expense for fiscal 2023 was $208.00K, a 93.37% decline from fiscal 2022.
- Syndax Pharmaceuticals, Inc. interest expense for fiscal 2022 was $3.14M, a 65.19% increase from fiscal 2021.
- Syndax Pharmaceuticals, Inc. interest expense for fiscal 2021 was $1.90M, a 19.43% decline from fiscal 2020.
- Syndax Pharmaceuticals, Inc. interest expense for fiscal 2020 was $2.36M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $45.00K 10-Q · filed 2024-08-01 | $100.00K 10-Q · filed 2024-08-01 | $163.00K derived: sum of 3 quarters · filed 2024-08-01 | $233.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2024-03-31 | $55.00K 10-Q · filed 2024-05-08 | $118.00K derived: sum of 2 quarters · filed 2024-05-08 | $188.00K derived: sum of 3 quarters · filed 2024-05-08 | $223.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $133.00K derived: sum of 2 quarters · filed 2024-02-27 | $168.00K derived: sum of 3 quarters · filed 2024-08-01 | $208.00K 10-K · filed 2024-02-27 |
| 2023-09-30 | $70.00K 10-Q · filed 2023-11-02 | $105.00K derived: sum of 2 quarters · filed 2024-08-01 | $145.00K 10-Q · filed 2023-11-02 | $188.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-06-30 | $35.00K 10-Q · filed 2024-08-01 | $75.00K 10-Q · filed 2024-08-01 | $118.00K derived: sum of 3 quarters · filed 2024-08-01 | $1.87M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $40.00K 10-Q · filed 2024-05-08 | $83.00K derived: sum of 2 quarters · filed 2024-05-08 | $1.83M derived: sum of 3 quarters · filed 2024-05-08 | $2.53M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.79M derived: sum of 2 quarters · filed 2024-02-27 | $2.49M derived: sum of 3 quarters · filed 2024-02-27 | $3.14M 10-K · filed 2024-02-27 |
| 2022-09-30 | $1.75M 10-Q · filed 2023-11-02 | $2.44M derived: sum of 2 quarters · filed 2023-11-02 | $3.09M 10-Q · filed 2023-11-02 | $3.09M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $695.00K 10-Q · filed 2023-08-03 | $1.35M 10-Q · filed 2023-08-03 | $1.34M derived: sum of 3 quarters · filed 2024-02-27 | $1.99M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $651.00K 10-Q · filed 2023-05-08 | $644.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.29M derived: sum of 3 quarters · filed 2024-02-27 | $1.93M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $642.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.28M derived: sum of 3 quarters · filed 2024-02-27 | $1.90M 10-K · filed 2024-02-27 |
| 2021-09-30 | $649.00K 10-Q · filed 2022-11-03 | $1.28M derived: sum of 2 quarters · filed 2022-11-03 | $1.91M 10-Q · filed 2022-11-03 | $2.54M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $634.00K 10-Q · filed 2022-08-08 | $1.26M 10-Q · filed 2022-08-08 | $1.89M derived: sum of 3 quarters · filed 2023-02-28 | $2.53M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $623.00K 10-Q · filed 2022-05-09 | $1.26M derived: sum of 2 quarters · filed 2023-02-28 | $1.89M derived: sum of 3 quarters · filed 2023-02-28 | $2.53M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $635.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.27M derived: sum of 2 quarters · filed 2023-02-28 | $1.91M derived: sum of 3 quarters · filed 2023-02-28 | $2.36M 10-K · filed 2023-02-28 |
| 2020-09-30 | $635.00K 10-Q · filed 2021-11-15 | $1.27M derived: sum of 2 quarters · filed 2021-11-15 | $1.72M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $638.00K 10-Q · filed 2021-08-09 | $1.09M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $449.00K 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |